These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20092398)

  • 1. Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.
    Pepine CJ
    Ann Med; 2010; 42(1):19-35. PubMed ID: 20092398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
    Fisher M; Folland E
    Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherothrombosis: management of patients at risk.
    Mas JL
    Int J Clin Pract; 2005 Apr; 59(4):407-14. PubMed ID: 15853855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergency department: first line of defense in preventing secondary stroke.
    Ovbiagele B
    Acad Emerg Med; 2006 Feb; 13(2):215-22. PubMed ID: 16436789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin resistance and atherothrombotic disease.
    Mason PJ; Jacobs AK; Freedman JE
    J Am Coll Cardiol; 2005 Sep; 46(6):986-93. PubMed ID: 16168280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke and atherothrombosis: an update on the role of antiplatelet therapy.
    Alexandrov AV; Alagona P
    Int J Stroke; 2008 Aug; 3(3):175-81. PubMed ID: 18705896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of antithrombotic drugs in artery disease.
    Gallus AS
    Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic drugs for the secondary prevention of ischemic stroke.
    Nenci GG; Goracci S
    Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet therapy and vascular disease: an update.
    Buch MH; Prendergast BD; Storey RF
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):249-75. PubMed ID: 21303843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients at risk of ischemic events for long-term secondary prevention.
    Brassard A
    J Am Acad Nurse Pract; 2009 Dec; 21(12):677-89. PubMed ID: 19958419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and stroke prevention.
    Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
    Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL;
    Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MATCH results: implications for the internist.
    Lutsep HL
    Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
    Kikano GE; Brown MT
    Mayo Clin Proc; 2007 May; 82(5):583-93. PubMed ID: 17511957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factor profile and management of cerebrovascular patients in the REACH Registry.
    Röther J; Alberts MJ; Touzé E; Mas JL; Hill MD; Michel P; Bhatt DL; Aichner FT; Goto S; Matsumoto M; Ohman EM; Okada Y; Uchiyama S; D'Agostino R; Hirsch AT; Wilson PW; Steg PG;
    Cerebrovasc Dis; 2008; 25(4):366-74. PubMed ID: 18337635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.